Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros U.S. Tech 100 Index (AUT100)
5/28/2026, 12:00:00 AM
The FDA approved a label expansion for TREMFYA® (guselkumab) for the treatment of adults with active psoriatic arthritis, making it the only IL-23 inhibitor with an indication for inhibiting the progression of structural damage.
Korean Translation
FDA, 활동성 건선성 관절염 성인 환자 치료를 위해 트렘피어®(구셀쿠맙)의 라벨 확장을 승인하여 구조적 손상 진행 억제 적응증을 가진 유일한 IL-23 억제제가 됨.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Cummins Inc. (CMI) · Earnings Release
Q2 2026 earnings release on 2026-08-04, for which high importance is estimated due to potential 10% price impact, is scheduled.
8/4/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM
Apple Inc (AAPL) · Earnings Release
Apple's Q3 2026 earnings release is expected on July 30, 2026; analysts forecast an EPS of approximately $1.86 forecasted. Low importance is estimated as the market impact is expected to be around 1%.
7/30/2026, 12:00:00 AM